Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study

Alberts, Steven R.; Horvath, William L.; Sternfeld, William C.; Goldberg, Richard M.; Mahoney, Michelle R.; Dakhil, Shaker R.; Levitt, Ralph; Rowland, Kendrith M.; Nair, Suresh; Sargent, Daniel J.; Donohue, John H.

doi:10.1200/jco.2005.07.740

Cited by 477 publications

(248 citation statements)

References 17 publications

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“…The recent phase II study of Alberts et al (2005) confirmed the efficacy of FOLFOX4 in the neoadjuvant setting, with 25 of the 42 (60%) assessable patients with nonoptimally resectable liver-only metastatic disease showing a reduction of tumour burden and 17 (40%) patients subsequently undergoing surgery following a median of 6 months of chemotherapy. A high recurrence rate of 71% after a median follow-up of 22 months was observed in this study for patients who underwent complete resection.…”

Section: Hepatic Resectionmentioning

confidence: 89%

Management of advanced colorectal cancer: state of the art

Saunders

Iveson

2006

Br J Cancer

View full text Add to dashboard Cite

Colorectal cancer (CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first-line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur.

show abstract

Section: Hepatic Resectionmentioning

confidence: 89%

Management of advanced colorectal cancer: state of the art

Saunders

Iveson

2006

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Similarly, two-stage hepatectomies in CRLM involve delayed re-hepatectomy after hypertrophy of the residual liver and may be used for large bilateral lesions in which a one stage resection of all the involved segments would lead to liver failure (19). Modern chemotherapeutic regimens combining 5-FU, folinic acid and oxaliplatin and/or irinotecan are associated with much higher response rates and can allow 10-30% of patients with initially unresectable CRLM to be successfully treated with liver surgery (20)(21)(22)(23).…”

Section: Discussionmentioning

confidence: 99%

Perioperative use of the LiMON method of indocyanine green elimination measurement for the prediction and early detection of post-hepatectomy liver failure

Carino

O’Reilly

Dajani

et al. 2009

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…5-Fluorouracil (5-FU), leucovorin and oxaliplatin (Oxa) represent a therapeutic regime (FOLFOX) commonly used in the treatment of patients with advanced colon cancer. [4][5][6] Resistance to therapy occurs in nearly all patients with metastatic colon cancer, and patients that acquire resistance have a disease progression with few therapeutic options. As the gain of drug resistance involves the acquisition of a new phenotype, we hypothesized that the generation of fused cells in metastatic colon cancer could represent a phenomenon responsible of MDR.…”

Section: Introductionmentioning

confidence: 99%

Cell fusion promotes chemoresistance in metastatic colon carcinoma

et al. 2012

View full text Add to dashboard Cite

Chemoresistance is an important concern in the treatment of metastatic colon cancer. It may emerge through selection of clones that are inherently resistant from the outset or through mechanisms acquired during treatment. Cell fusion represents an efficient means of rapid phenotypic evolution that make cells with new properties at a rate exceeding that achievable by random mutagenesis. Here, we first identified a number of proteins involved in cell fusion using a shotgun proteomics approach, then we investigated the role of these proteins namely tetraspanin CD81/CD9, ADAM10, GTP-binding protein a13, radixin, myosin regulatory light chain and RhoA in the regulation of colon cancer cell fusion. We also found a previously unrecognized role of ADAM10, Ga13 and RhoA in promoting cell fusion. Finally, we show that the occurrence of cell fusion in a metastatic model of colon carcinoma causes the appearance of cells resistant to both 5-fluorouracil and oxaliplatin. These findings highlight the importance of cell fusion in cancer progression and raise significant implications for overcoming chemoresistance in metastatic colon cancer.

show abstract

Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study

Cited by 477 publications

References 17 publications

Management of advanced colorectal cancer: state of the art

Management of advanced colorectal cancer: state of the art

Perioperative use of the LiMON method of indocyanine green elimination measurement for the prediction and early detection of post-hepatectomy liver failure

Cell fusion promotes chemoresistance in metastatic colon carcinoma

Contact Info

Product

Resources

About